Evolus, Inc. Common Stock EOLS
i
Market dataready · fetched 2026-11-05T15:12:50.195Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-05T15:12:27.708242687Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-05T15:12:49.370922+00:00
Evolus, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.70 | 261.9% | 32.9% | |||
| 25Δ | 6.28 | 313.6% | 32.4% | |||
| 30Δ | 8.66 | 125.2% | 26.6% | 6.86 | 365.3% | 31.9% |
| 35Δ | 8.36 | 129.3% | 23.5% | 7.44 | 417.0% | 31.4% |
| 40Δ | 8.05 | 133.3% | 20.3% | 7.91 | 397.1% | 27.9% |
| 45Δ | 7.75 | 137.4% | 17.1% | 8.36 | 369.4% | 24.1% |
| 50Δ | 7.45 | 140.5% | 14.2% | 8.82 | 341.7% | 20.3% |
| 55Δ | 7.18 | 138.4% | 12.7% | 9.27 | 314.1% | 16.5% |
| 60Δ | 6.90 | 136.4% | 11.2% | 9.73 | 286.4% | 12.7% |
| 65Δ | 6.62 | 134.3% | 9.7% | 11.48 | 306.4% | 10.4% |
| 70Δ | 6.34 | 132.3% | 8.2% | |||
| 75Δ | 6.06 | 130.2% | 6.6% | |||
| 80Δ | 5.78 | 128.1% | 5.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.70
- IV
- 261.9%
- B/E move
- 32.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.28
- IV
- 313.6%
- B/E move
- 32.4%
30Δ
- Pseudo strike
- 8.66
- IV
- 125.2%
- B/E move
- 26.6%
- Pseudo strike
- 6.86
- IV
- 365.3%
- B/E move
- 31.9%
35Δ
- Pseudo strike
- 8.36
- IV
- 129.3%
- B/E move
- 23.5%
- Pseudo strike
- 7.44
- IV
- 417.0%
- B/E move
- 31.4%
40Δ
- Pseudo strike
- 8.05
- IV
- 133.3%
- B/E move
- 20.3%
- Pseudo strike
- 7.91
- IV
- 397.1%
- B/E move
- 27.9%
45Δ
- Pseudo strike
- 7.75
- IV
- 137.4%
- B/E move
- 17.1%
- Pseudo strike
- 8.36
- IV
- 369.4%
- B/E move
- 24.1%
50Δ
- Pseudo strike
- 7.45
- IV
- 140.5%
- B/E move
- 14.2%
- Pseudo strike
- 8.82
- IV
- 341.7%
- B/E move
- 20.3%
55Δ
- Pseudo strike
- 7.18
- IV
- 138.4%
- B/E move
- 12.7%
- Pseudo strike
- 9.27
- IV
- 314.1%
- B/E move
- 16.5%
60Δ
- Pseudo strike
- 6.90
- IV
- 136.4%
- B/E move
- 11.2%
- Pseudo strike
- 9.73
- IV
- 286.4%
- B/E move
- 12.7%
65Δ
- Pseudo strike
- 6.62
- IV
- 134.3%
- B/E move
- 9.7%
- Pseudo strike
- 11.48
- IV
- 306.4%
- B/E move
- 10.4%
70Δ
- Pseudo strike
- 6.34
- IV
- 132.3%
- B/E move
- 8.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 6.06
- IV
- 130.2%
- B/E move
- 6.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.78
- IV
- 128.1%
- B/E move
- 5.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 220.65% | |
| 98.36% | |
| 155.81% | |
| 150.32% | |
| 80.68% | |
| 93.61% | |
| 84.23% | |
| 89.48% | |
| 129.46% | |
| 104.30% | |
| 73.28% | |
| 73.22% | |
| 83.78% | |
| 83.24% | |
| 116.05% | |
| 109.02% | |
| 124.43% | |
| 107.01% | |
| 90.83% |
Drug Manufacturers - Specialty & Generic
ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park,…
More →GLAS
Description unavailable
More →HCM
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central,…
More →HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San…
More →HLN
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust…
More →HROW
Description unavailable
More →